ArticleScience signaling2021
mTORC2 controls the activity of PKC and Akt by phosphorylating a conserved TOR interaction motif.
Open access · greenAbstract read
In one paragraph
Article in Science signaling, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
6.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 109 citations in OpenAlex.
- Suppression of AKT Activation Through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers.Molecular cancer therapeutics · 2026Article
- Sex-specific disruptions in PKCγ signaling in a mouse model of spinocerebellar ataxia type 14.JCI insight · 2026Article
- Differential regulation of monocyte exhaustion by distinct TLR agonists and underlying mechanisms.Cell communication and signaling : CCS · 2026Article
- Protein kinase C theta: evolution, regulation, and function.The Biochemical journal · 2026Review
- Structural basis for the recruitment and selective phosphorylation of Akt by mTORC2.Science (New York, N.Y.) · 2026Article
- Structural and mechanistic basis of mTORC2 activation of protein kinase AKT/PKB.The Biochemical journal · 2026Review
- PI3K/PKB signaling network as a host target to enhance bacterial ingestion and clearance.Biologia futura · 2026Review
- mTORC1/2 inhibition induces tumor regression in CDK4/6 inhibitor-insensitive acral melanoma.Cancer gene therapy · 2026Article
- Discovery of Lomitapide as a Novel Mast Cell Regulatory Agent Through Chemical Library Screening.European journal of immunology · 2026Article
- mTOR in radiotherapy of lung cancer: Mechanisms of radiation resistance and therapeutic implications (Review).International journal of oncology · 2026Review
- mTOR signaling governs the formation of epithelial apical projections via S6K1-RhoA and aPKC-Lgl2 axes.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- PTEN-mTORC2 signaling module controls antibody isotype selection and antiviral humoral immunity.Frontiers in immunology · 2026Article
- Research on the correlation and potential mechanism of PKCδ expression with efficacy and prognosis in diffuse large B-cell lymphoma.Frontiers in oncology · 2026Article
- Cell Type-Specific mTORC1 Signaling and Translational Control in Synaptic Plasticity and Memory.Journal of neurochemistry · 2025Review
- Autosomal Dominant Polycystic Kidney Disease: From Pathogenesis to Organoid Disease Models.Biomedicines · 2025Review
- Regulation of Rho guanine nucleotide exchange factor 3 by phosphorylation in the PH domain.iScience · 2025Article
- Hypercapnia Increases Influenza A Virus Infection of Bronchial Epithelial Cells by Augmenting Cellular Cholesterol via mTOR and Akt.International journal of molecular sciences · 2025Article
- Article
- Illuminating understudied kinases: a generalizable biosensor development method applied to protein kinase N.Communications biology · 2025Article
- The β-adrenergic receptor-SGK1 signaling pathway in brown adipocytes protects GOT1 from proteasomal degradation.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Timothy R BaffiDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.ORCID 0000-0003-2862-6155
Gema LordénDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9674-890X
Jacob M WozniakDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.
Andreas FeichtnerInstitute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, Innsbruck A-6020, Austria.ORCID 0000-0002-9376-6229
Wayland YeungInstitute of Bioinformatics, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0002-2523-4984
Alexandr P KornevDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-1543-3795
Charles C KingDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.
Jason C Del RioDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.
Ameya J LimayeDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0002-3582-8858
Julius BogomolovasDepartment of Medicine, University of California at San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-8344-1909
Christine M GouldDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.ORCID 0000-0003-3999-0649
Ju ChenDepartment of Medicine, University of California at San Diego, La Jolla, CA 92093, USA.
Eileen J KennedyDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0001-5610-1677
Natarajan KannanInstitute of Bioinformatics, University of Georgia, Athens, GA 30602, USA.ORCID 0000-0002-2833-8375
David J GonzalezDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.
Eduard StefanInstitute of Biochemistry and Center for Molecular Biosciences, University of Innsbruck, Innsbruck A-6020, Austria.ORCID 0000-0003-3650-4713
Susan S TaylorDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-7702-6108
Alexandra C NewtonDepartment of Pharmacology, University of California at San Diego, La Jolla, CA 92093, USA. anewton@health.ucsd.edu.ORCID 0000-0002-2906-3705
University of California San Diego · USUniversity of Georgia · USUniversität Innsbruck · AT
Funding
GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5MTraining In Cardiovascular Physiology & PharmacologyT32HL007444 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen, Robert Scott Ross · 1985 to 2026
$11.1MMolecular Mechanisms of Cell SignalingR35GM122523 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALEXANDRA C. NEWTON · 2017 to 2026
$6.7MLessons Learned from PKA: Assembly of Dynamic Macromolecular SwitchesR35GM130389 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN S. TAYLOR · 2019 to 2026
$5.7MStructure, Function and Regulation of Protein Kinase CR37GM043154 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NEWTON, ALEXANDRA C. · 2003 to 2012
$4.0MRheumatic Diseases Research Training GrantT32AR064194 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GARY S FIRESTEIN, Monica Guma · 2013 to 2026
$3.8MSTRUCTURE/FUNCTION AND REGULATION OF PROTEIN KINASE CR01GM043154 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NEWTON, ALEXANDRA C. · 1990 to 2016
$2.5MProtein Kinase Novel 2 (PKN2) in heartR01HL155826 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, JU · 2021 to 2024
$2.2MFunctional Annotation of Natural and Disease Variants in Tryosine KinasesR01GM114409 · NIGMS · UNIVERSITY OF GEORGIA · PI KANNAN, NATARAJAN · 2015 to 2020
$1.6MA data analytics framework for mining the dark kinomeU01CA239106 · NCI · UNIVERSITY OF GEORGIA · PI KANNAN, NATARAJAN, KOCHUT, KRZYSZTOF J · 2019 to 2021
$1.3MTargeting WASF3 to suppress metastasisR01GM134168 · NIGMS · UNIVERSITY OF GEORGIA · PI KENNEDY, EILEEN J · 2019 to 2022
$1.2MAustrian Science Fund FWF P 30441NCI NIH HHS U01 CA239106NHLBI NIH HHS R01 HL155826NHLBI NIH HHS T32 HL007444NIAMS NIH HHS T32 AR064194NIGMS NIH HHS R01 GM043154NIGMS NIH HHS R01 GM114409NIGMS NIH HHS R01 GM134168NIGMS NIH HHS R35 GM122523NIGMS NIH HHS R35 GM130389NIGMS NIH HHS R37 GM043154NIGMS NIH HHS T32 GM007752
Abstract
The complex mTORC2 is accepted to be the kinase that controls the phosphorylation of the hydrophobic motif, a key regulatory switch for AGC kinases, although whether mTOR directly phosphorylates this motif remains controversial. Here, we identified an mTOR-mediated phosphorylation site that we termed the TOR interaction motif (TIM; F-x
Indexed as
Mechanistic Target of Rapamycin Complex 2PeptidesProtein Kinase CProto-Oncogene Proteins c-aktAmino Acid MotifsAnimalsMicePhosphorylationMechanistic Target of Rapamycin Complex 2PeptidesProtein Kinase CProto-Oncogene Proteins c-akt
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.